Exact Sciences (EXK) Price & Analysis

Compare

4 Followers

EXK Stock Chart & Stats

€87.05

-€1.13(-2.05%)

At close: Jan 08 4:00 PM EST

€87.05

-€1.13(-2.05%)

Day’s Range― - ―

52-Week Range€33.80 - €88.16

Previous CloseN/A

Volume60.00

Average Volume (3M)60.00

Market Cap

€16.60B

Enterprise Value€11.89B

Total Cash (Recent Filing)€1.00B

Total Debt (Recent Filing)€2.54B

Price to Earnings (P/E)―

Beta-0.34

Next Earnings

Feb 24, 2026

EPS Estimate

-0.07

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding189,765,820

10 Day Avg. Volume88

30 Day Avg. Volume60

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)4.31

Price to Sales (P/S)3.75

P/FCF Ratio138.84

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€82.84

Price Target Upside-4.83% Downside

Rating ConsensusHold

Number of Analyst Covering21

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Acquisition ImpactThe acquisition by Abbott is seen as a 'watershed' moment in the diagnostics industry, which could enhance sector valuations and lead to more mergers and acquisitions.

Growth And ProfitabilityAbbott's strategic interest in Exact Sciences is driven by its accelerating growth, profitability, and position in preventative, predictive, and personalized diagnostics.

Market ExpansionAbbott plans to expand the total addressable market by $40B+ with EXAS, adding a whole new growth vertical to its business.

Bears Say

Future Dilution RiskExact Sciences is expected to be dilutive in '26 and '27, but Abbott plans to return back to double-digit EPS growth in 2027.

High Acquisition CostThe $23 billion enterprise value price is considered high, which could deter other companies from placing a competing bid for Exact Sciences.

Limited Upside PotentialThe analyst downgraded Exact Sciences to a HOLD rating due to the limited upside potential of less than 5% from the current share price to the $105 offer.

Exact Sciences News

Exact Sciences downgraded to Hold from Buy at Stifel

Stifel downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $80,...

1d ago

EXAS

Private Markets: Prediction market platform Kalshi secures $300M

Kalshi, the prediction market platform, has raised a $300M Series D funding round. This week’s private company news:...

1d ago

CME

Brinker upgraded, Coinbase downgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

4d ago

Exact Sciences downgraded to Hold from Buy at Canaccord

Canaccord downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $85,...

5d ago

EXAS

Exact Sciences downgraded to Hold from Buy at TD Cowen

TD Cowen downgraded Exact Sciences (EXAS) to Hold from Buy with a $105 price target after the company...

5d ago

EXAS

Exact Sciences downgraded to Neutral from Overweight at Piper Sandler

Piper Sandler analyst David Westenberg downgraded Exact Sciences (EXAS) to Neutral from Overweight with a $105 price target...

5d ago

EXAS

Booking, Carvana upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

5d ago

Exact Sciences downgraded to Hold from Buy at Benchmark

Benchmark downgraded Exact Sciences (EXAS) to Hold from Buy after the company announced an agreement to be acquired...

6d ago

EXAS

Exact Sciences downgraded to Hold from Buy at Jefferies

Jefferies downgraded Exact Sciences (EXAS) to Hold from Buy with a price target of $105, up from $90,...

6d ago

ABT

EXAS

Cathie Wood Loads Up on CoreWeave (CRWV), and Crypto Stocks; Trims Stakes in GitLab, AMD, and Other Tech Stocks

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) reported new trades on Friday, November 10, according to daily fund disclosures. ARK bought shares...

6d ago

AMD

ARKB

Cathie Wood Buys Nvidia, ACHR and Crypto Stocks, Offloads AMD, EXAS

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio adjustments on Thursday, November 20, as revealed in daily...

8d ago

AMD

ACHR

Exact Sciences downgraded to Hold from Buy at Craig-Hallum

Craig-Hallum analyst Bill Bonello downgraded Exact Sciences (EXAS) to Hold from Buy with a $105 price target after...

8d ago

EXAS

3 Best Dividend Aristocrat Stocks to Buy Now, 11/21/2025

Looking for a reliable income from your investments? One proven path is through dividend aristocrats. What Are Dividend...

8d ago

ABT

CAT

Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Earnings reports, mergers, and other data are among the top stock market stories on Thursday. ...

9d ago

EXK FAQ

What was Exact Sciences Corp’s price range in the past 12 months?

Exact Sciences Corp lowest stock price was €33.80 and its highest was €88.16 in the past 12 months.

What is Exact Sciences Corp’s market cap?

Exact Sciences Corp’s market cap is €16.60B.

When is Exact Sciences Corp’s upcoming earnings report date?

Exact Sciences Corp’s upcoming earnings report date is Feb 24, 2026 which is in 86 days.

How were Exact Sciences Corp’s earnings last quarter?

Exact Sciences Corp released its earnings results on Nov 03, 2025. The company reported -€0.086 earnings per share for the quarter, missing the consensus estimate of -€0.053 by -€0.034.

Is Exact Sciences Corp overvalued?

According to Wall Street analysts Exact Sciences Corp’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Exact Sciences Corp pay dividends?

Exact Sciences Corp does not currently pay dividends.

What is Exact Sciences Corp’s EPS estimate?

Exact Sciences Corp’s EPS estimate is -0.07.

How many shares outstanding does Exact Sciences Corp have?

Exact Sciences Corp has 189,765,820 shares outstanding.

What happened to Exact Sciences Corp’s price movement after its last earnings report?

Exact Sciences Corp reported an EPS of -€0.086 in its last earnings report, missing expectations of -€0.053. Following the earnings report the stock price went up 5.456%.

Which hedge fund is a major shareholder of Exact Sciences Corp?

Currently, no hedge funds are holding shares in DE:EXK

Exact Sciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

-34.54%

Trailing 12-Months

Asset Growth

-12.57%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Exact Sciences (EXK) Earnings & Revenues

Historic Earnings Reports

EXK Company Deck

EXK Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

Exact Sciences reported strong financial and operational performance with significant revenue growth driven by Cologuard and new product launches. However, there were challenges in maintaining gross margins and completing payer contracts for Cologuard Plus.View all DE:EXK earnings summaries

EXK Revenue Breakdown

74.59% Screening

25.17% Precision Oncology

0.24% COVID-19 Testing

EXK Stock 12 Month Forecast

Average Price Target

€82.84

▼(-4.83% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"€38","91":"€91","51.25":"€51.3","64.5":"€64.5","77.75":"€77.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":90.5524473,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€90.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":82.8425532156,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€82.84</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":43.120213,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€43.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,51.25,64.5,77.75,91],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.88,58.54711133076923,61.214222661538464,63.881333992307695,66.54844532307692,69.21555665384615,71.88266798461538,74.54977931538461,77.21689064615384,79.88400197692307,82.5511133076923,85.21822463846154,87.88533596923077,{"y":90.5524473,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.88,57.95404255504616,60.02808511009231,62.10212766513847,64.17617022018462,66.25021277523078,68.32425533027693,70.39829788532307,72.47234044036924,74.5463829954154,76.62042555046155,78.6944681055077,80.76851066055386,{"y":82.8425532156,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,55.88,54.898477923076925,53.91695584615385,52.93543376923077,51.95391169230769,50.972389615384614,49.99086753846154,49.00934546153846,48.02782338461539,47.04630130769231,46.06477923076923,45.083257153846155,44.10173507692308,{"y":43.120213,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.14,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.63,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.82,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.8,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.76,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.12,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.025,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.805,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.205,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.88,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >